DA-9701-R Placebo

Phase 3

DDong-A ST Co., Ltd.

DA-9701-R Placebo is one of 3 therapeutic programs targeting Functional Dyspepsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Functional DyspepsiaRecruiting

Functional DyspepsiaPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Functional Dyspepsia

#DrugCompanyPhaseTrials

Nereus

VVanda Pharmaceuticals

Phase 2

1 2

DA-9701-R Placebo

DDong-A ST Co., Ltd.

Phase 3

1 3

DA-9701

SSeoul National University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Functional Dyspepsia

NCT07686679

Clinical

Trials by Indication[1]

Functional Dyspepsia1 trial

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia

Recruiting·DDong-A ST Co., Ltd.·Approved·NCT07686679·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DA-9701-R Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for DA-9701-R Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Dong-A ST Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDong-A ST Co., Ltd.

DA-9701-R Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Functional Dyspepsia1 trial

References

Drug Info

Quick Facts

Related News